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A B S T R A C T
Objectives: The medial temporal lobe atrophy (MTA) and the posterior atrophy (PA) scales allow to assess the
degree hippocampal and parietal atrophy from magnetic resonance imaging (MRI) scans. Despite reliable, easy
and widespread employment, appropriate normative values are still missing. We aim to provide norms for the
Italian population.
Methods: Two independent raters assigned the highest MTA and PA score between hemispheres, based on 3D T1-
weighted MRI of 936 Italian Brain Normative Archive subjects (age: mean± SD: 50.2± 14.7, range: 20–84;
MMSE>26 or CDR=0). The inter-rater agreement was assessed with the absolute intraclass correlation coef-
ficient (aICC). We assessed the association between MTA and PA scores and sociodemographic features and
APOE status, and normative data were established by age decade based on percentile distributions.
Results: Raters agreed in 90% of cases for MTA (aICC=0.86; 95% CI= 0.69–0.98) and in 86% for PA
(aICC=0.82; 95% CI= 0.58–0.98). For both rating scales, score distribution was skewed, with MTA=0 in
38% of the population and PA=0 in 52%, while a score≥ 2 was only observed in 12% for MTA and in 10% for
PA. Median denoted overall hippocampal (MTA: median=1, IQR=0–1) and parietal (PA: median= 0,
IQR=0–1) integrity. The 90th percentile of the age-specific distributions increased from 1 (at age 20–59) for
both scales, to 2 for PA over age 60, and up to 4 for MTA over age 80. Gender, education and APOE status did not
significantly affect the percentile distributions in the whole sample, nor in the subset over age 60.
Conclusions: Our normative data for the MTA and PA scales are consistent with previous studies and overcome
their main limitations (in particular uneven representation of ages and missing percentile distributions), defining
the age-specific norms to be considered for proper brain atrophy assessment.
1. Introduction
In Alzheimer's disease (AD), neurodegeneration progresses from the
hippocampus, towards the temporal lobes and the fronto-parietal
associative areas, along with the underlying tauopathy, as demon-
strated by neuropathological and neuroimaging studies (Braak and
Braak, 1991; Marquié et al., 2017). Atrophy of the medial temporal and
parietal lobe is thus common, although not specific, of AD. Volumetric
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studies of these areas show a 10% volume decrease in patients with
mild cognitive impairment (MCI) due to AD (Chan et al., 2003; Frisoni
et al., 2009) and a correlation of these volumes with the severity of
cognitive impairment (Burke et al., 2018). Consistently, hippocampal
atrophy and parietal atrophy are significant predictors of progression
from MCI to dementia, most frequently due to AD (DeCarli et al., 2007;
Jack et al., 1999; Da et al., 2013; Pyun et al., 2017; Yao et al., 2012).
Thus, the usual employment of MRI with exclusionary role at the be-
ginning of the diagnostic procedure can also have an inclusionary role
to diagnose AD and related disorders.
The most informative volumetric measurements to this avail, re-
quiring manual or semi-automated segmentation of the regions of in-
terest, are time-consuming and require specific technical expertise.
Visual rating scales allow a reliable but more feasible assessment of
brain atrophy on MRI, mainly for clinical, but also research purposes
(Scheltens et al., 1992; Koedam et al., 2011). The medial temporal
atrophy (MTA) scale assesses the width of the choroid fissure and of the
temporal horn, as well as the height of the hippocampus; the posterior
atrophy (PA) scale assesses the width of the posterior cingulate- and
parieto-occipital sulci, and the atrophy of the parietal lobe and pre-
cuneus. These scales demonstrated a similar accuracy in distinguishing
healthy controls from subjects affected by dementia, especially due to
AD, as automated measurement methods (Scheltens et al., 1992; Harper
et al., 2016).
Different age-corrected cutoffs distinguishing AD dementia from
normal aging were proposed, both for MTA (Scheltens et al., 1992;
Pereira et al., 2014; Ferreira et al., 2015; Rhodius-Meester et al., 2017)
and PA (Koedam et al., 2011; Ferreira et al., 2015; Rhodius-Meester
et al., 2017). Cut-off values increase with age, denoting that a certain
degree of hippocampal and parietal atrophy may occur also in normal
aging. The distribution of MTA and PA scores in normal subjects can be
inferred from the control groups in clinical studies. In Scheltens' and
Koedam's original papers, most control subjects (67% and 88%, re-
spectively) had an atrophy score of 0 or 1. Similar distributions were
reported in further studies (Pereira et al., 2014; Ferreira et al., 2015;
Rhodius-Meester et al., 2017), concluding that an MTA or PA score of 1
can be considered as normal. Population-based studies are un-
fortunately scarce. In 555 non-demented elderly individuals from the
longitudinal study of aging “Swedish National study of Ageing and Care
in Kungsholmen”, aged between 60 and 97, Cavallin et al. (2012)
confirmed that an MTA score of 0–1 is present in 95% of subjects aged
60- and 66-years old, a score of 0–2 in 98% of 72 and 78–years old, and
a score of 0–3 in 99% of subjects over age 80. Consistently, a recent
study in a homogeneous 75-year-old population-based cohort of 390
individuals from the “Prospective Investigation of the Vasculature in
Uppsala Seniors”, found that a MTA score≤ 2 can be considered
normal at the age of 75 (Velickaite et al., 2018). However, these values
are obtained from small size samples with arbitrarily homogeneous age
ranges (i.e., only 60, 66, 72, 75, 78, 81, 84, and over-87 years olds)
(Cavallin et al., 2012; Velickaite et al., 2018), and do not provide in-
formation on the percentile distribution of MTA scores. On the other
hand, studies of PA normative distribution in population-based samples
are still missing.
The normal shrinkage in hippocampus and parietal lobe is larger
than any other brain structure in normal aging (Jernigan et al., 2001;
Lemaitre et al., 2012; Thambisetty et al., 2010), and may be modulated
by specific confounders. To date, the reported relation between APOE
genotype and the rate of volume loss is inconsistent in both brain re-
gions (Soldan et al., 2015; Burggren et al., 2008; Chiang et al., 2011;
Luo et al., 2017). However, gender and education were associated to
the degree of hippocampal atrophy, with higher MTA scores being
observed in men and in subjects with higher education (Velickaite
et al., 2018).
The aim of this study was to establish normative data for the MTA
and PA scales for the Italian population, considering the potential
confounding role of gender, education and APOE genotype.
2. Materials and methods
2.1. Study population and design
We collected data from the “Italian Brain Normative Archive”, a
study on normal brain aging performed between 2001 and 2008 at the
IRCCS Istituto Centro San Giovanni di Dio-Fatebenefratelli, in Brescia
(Riello et al., 2005; Galluzzi et al., 2009). Participants were 802 cog-
nitively unimpaired subjects selected from those undergoing brain MRI
scan for reasons unrelated to cognition (“convenience” sample). Rea-
sons to perform MRI were visual disturbances, paresthesias, migraine or
headache, balance or auditory disturbances (hypoacusia, dizziness,
tinnitus), and a variety of other less frequent complaints (olfactory
symptoms; suspected ischemic lesions, syncope, trigeminal neuralgia,
tremor, lower limb pain, orbital region study, lipothymia and breathing
difficulty). A sample of 134 subjects participated as healthy volunteers
undergoing MRI scan uniquely for research purposes.
Inclusion criteria included: (i) age>18 years, (ii) mini mental state
examination (MMSE) score> 26 (in person (Folstein et al., 1975) or
telephone version (Metitieri et al., 2001)) or a score equal to 0 at the
Clinical Dementia Rating Scale (CDR), (iii) availability of 3D T1-
weighted MR images with no artifacts affecting atrophy assessment
with MTA and PA scales. As exclusion criteria, we considered: devel-
opmental cognitive disorders, learning disabilities, diagnosis of a psy-
chiatric disease and evidence of any major neurological disease (brain
mass, white matter hyperintensities in patients undergoing MRI for
suspected multiple sclerosis or suspected ischemic lesions, aneurysm
larger than 10mm, arteriovenous malformation besides developmental
venous anomalies, congenital malformations of the central nervous
system) after radiological assessment. If neurological symptoms were
reported, subjects were enrolled only in the absence of objective neu-
rological deficits on neurological examination.
All included subjects underwent multidimensional assessment, in-
cluding clinical, neurological and neuropsychological evaluations. An
extensive neuropsychological battery investigated global, verbal and
non-verbal memory, verbal fluency, psychomotor speed and visuo-
spatial abilities (Table S1). Subjects were enrolled in the study if neu-
ropsychological assessment attested a normal cognitive performance
(more detailed information is reported elsewhere (Galluzzi et al., 2009;
Riello et al., 2005)).
For each atrophy scale, we compared the score distributions of the
convenience sample (N=802) and of the healthy volunteers (N=134)
to ascertain the representativity of the convenience sample. We defined
the normative values using the whole sample of 936 subjects, after
dividing it into seven age decades. The effect of gender, education and
APOE was assessed on the whole sample and on the subsample of
subjects over age 60.
The study was approved by the ethics committee of IRCCS Istituto
Centro San Giovanni di Dio-Fatebenefratelli of Brescia, and carried out
in accordance with the Declaration of Helsinki. Participants or their
legal representatives provided written informed consent of participa-
tion in the study. No participant received financial compensation.
2.2. Magnetic resonance imaging
MRI scans were acquired in the Neuroradiology Units of “Città di
Brescia” Hospital and of “Fondazione Poliambulanza”, in Brescia
(Italy), from March 2001 to December 2008, using two different scan-
ners following the same standardized protocol. For this study we ana-
lysed 722 3D T1-weighted sequences acquired with (a) Gyroscan Intera
1 T (Philips Medical Systems, Best, Netherlands), and 214 with (b)
Signa Excite 1.5 T (GE Healthcare, Waukesha, WI, USA). MTA and PA
were rated on images acquired with the following parameters: (a)
TR=20ms; TE=2ms; flip angle= 30°; FOV=220mm; acquisition
matrix, 256× 256; slice thickness= 1.3mm; (b) TR=21ms,
TE= 20ms, flip angle= 10°, FOV=256mm, acquisition matrix
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256×256, slice thickness= 2mm.
2.3. Visual rating
Based on Scheltens' original description (Scheltens et al., 1992),
MTA scale was rated on 3D T1-weighted MR images, on the coronal
slice parallel to the brainstem axis and passing through the aqueduct of
Silvius. On this slice, we assessed both hemispheres providing a 0–4
score according to the following criteria: 0 no atrophy, 1 widening of
the choroid fissure, 2 additional widening of the temporal horn of the
lateral ventricle and slightly decreased hippocampal height, 3 moderate
loss of hippocampal volume, and 4 end-stage increase of all these
findings. Rating of PA was performed after evaluation on three ortho-
gonal slices (paramedian sagittal, axial and coronal) passing through
the parietal lobe. For both hemispheres we provided a 0–3 score de-
noting: 0 no atrophy, 1 mild widening of the sulci without evident
volume loss of the parietal gyri, 2 substantial widening of the sulci and
volume loss of the gyri, and 3 knife-blade atrophy (Koedam et al., 2011)
(Fig. 1).
Visual ratings were performed by two independent raters (MCR and
RB) after appropriate training by an experienced reader (CF for MTA,
and SI for PA, both with >3 years of experience in the visual rating and
over 2500 neuroimages assessed from LANE and EPAD datasets). For
each scale, in case of between-rater discordance in the highest score
between the two hemispheres, the images were collegially re-discussed
by raters in order to reach a final consensus. As most of the discordant
scores differed by only one point, mainly due to evaluations performed
on adjacent slices by the raters, in many cases the final consensus was
easily obtained choosing the slice in which atrophy was more evident
and better assessable; in the other cases, the experienced reader was
consulted. Percentile data were computed per decade on the consensual
scores.
2.4. Genetic analysis
Blood samples were available for 530 subjects. Genomic DNA was
extracted from whole-blood samples according to standard procedures.
APOE genotyping was carried out by PCR amplification and HhaI re-
striction enzyme digestion. Genotypes were resolved on 4% Metaphor
Gel (BioSpa, Italy) and visualized by ethidium bromide staining (Hixson
and Vernier, 1990).
2.5. Statistical analyses
The inter-rater reliability was estimated with a two-way random
effects model of the intraclass correlation coefficient with absolute
agreement (aICC), that accounts not only for correlations but also for
the concordance of the absolute value of the measurement, based on the
highest scores between hemispheres. Agreement was considered poor
for aICC<0.50, moderate for aICC 0.50–0.75, good with aICC
0.75–0.90, and excellent for aICC>0.90 (Koo and Li, 2016).
Normative data were calculated on the consensual highest scores
and the 50th and 90th percentiles were computed for each age decade.
In order to assess the influence of gender, education and APOE status on
the 50th and 90th percentiles, we used Chi square test for categorical
variables, or Kruskal Wallis test and post-hoc Nemenyi test for non-
normally distributed continuous variables. Moreover, we compared the
scores distributions of the convenience sample and of the healthy vo-
lunteers with the Chi square to assess the goodness of fit (Table S2). All
statistical analyses were conducted using R (version 3.3.3).
3. Results
3.1. Demographic and clinical features
Sociodemographic features, APOE, and cognitive status in the total
sample and by age decades are summarized in Table 1. Individuals were
continuously distributed in all age decades, prevailing between the fifth
and the eight decade (72% between 40 and 79 years). The male-to-fe-
male ratio was equally distributed and consistent across all decades
(p= .144), while education was significantly lower with increasing age
(p< .001).
Fig. 1. Visual rating of MTA and PA scales.
PA visual rating is assessed on three orthogonal slice (coronal, sagittal, axial), with particular attention to precuneus (PRE), posterior cingulate sulcus (PCS), parieto-
occipital sulcus (POS) and parietal lobe (PAR) (top panel). On the contrary, MTA visual rating is performed on a single coronal slice including hippocampus, with
particular attention to the width of the choroid fissure and of the temporal horn, and to the hippocampus height (bottom panel).
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3.2. Inter-rater reliability
Raters reached a good agreement for both scales, agreeing in 90% of
individually rated images for MTA (aICC=0.86, 95% CI: 0.69–0.98)
and in 86% for PA (aICC=0.82, 95% CI: 0.58–0.98). Among the MRI
scans with discordant rating, only 3 (0.3%) for MTA and only 1 (0.1%)
for PA differed by 2 points.
3.3. Normative data
The distribution of the consensual scores was skewed for both rating
scales, with 358 participants (38%) scoring MTA=0, and 489 (52%)
scoring PA=0. Only 109 (12%) and 95 (10%) participants scored 2 or
more, respectively for MTA and PA. No significant differences in the
scores distribution were detected between the convenience sample and
the healthy volunteers subgroup. Score distribution for each scale is
reported in Fig. 2 (on the left). Median indicated a general integrity of
the hippocampus (median= 1, IQR=0–1) and of the parietal lobe
(median=0, IQR=0–1) in the overall sample. The normative data per
age decade are reported in Table 2. MTA and PA correlated positively
with age (MTA: p< .001; PA: p< .001). The 90th percentile increased
from 1 at age 20–59 to 2 at age 60–79, up to 4 over 80 years of age for
MTA, while PA went from 1 at age 20–59 to 2 over 60 (Fig. 2, on the
right). The prevalence of APOE-ε4 carriers did not differ significantly
below and over the 90th percentile, both for MTA (19% vs 18%,
p=1.00) and PA (19% vs 13%, p=1.00).
3.4. Effects of clinical features and APOE-ε4 on atrophy severity
Among the evaluated sociodemographic features (i.e. age, gender
and education), older age was associated with significantly greater
scores in both scales (p< .001). In particular, MTA increased pro-
gressively from the sixth decade of life up to the ninth, with a sig-
nificant increase between the sixth and the seventh decade (p= .006),
while PA increased from the third decade up to the ninth, with a sig-
nificant increase between the fifth and sixth (p= .005) and between the
sixth and the seventh (p< .001). No significant association of gender
and education was found with MTA, while a trend to higher scores was
observed in men than women in the last two decades (age 70–79:
median (IQR): F= 1(0–1), M=2(1–2), p= .073; age≥80:
F= 1(0–1), M=3(1–3), p= .056). In the total sample, gender showed
a significant effect on PA, with males scoring higher than females
(p= .010). However, no significant difference was observed in the
percentile distributions by age group. No significant association was
found between PA and education. Likewise, APOE-ε4 status was not
associated with neither MTA nor PA severity, in both the whole sample
and in the subset of subjects over 60 years of age.
4. Discussion
With this study, we provide the normative data for the MTA and PA
scales for the Italian population, based on a large sample of cognitively
intact community-dwelling persons with age continuously distributed
from 20 to 84. This normative distribution of MTA and PA values will
help to assess data from individual patients. However, we recommend
that these be considered within the whole clinical and biomarker as-
sessment; we also remind that the definition of specific disease cutoffs
require independent studies including appropriate target patient
groups.
In previous studies, the hippocampal and parietal atrophy were
investigated in cognitively normal subjects (from control groups)
mainly with the aim to detect the MTA and PA cut-offs distinguishing
AD from normal aging with best accuracy (Scheltens et al., 1992;
Koedam et al., 2011; Pereira et al., 2014; Ferreira et al., 2015; Rhodius-
Meester et al., 2017). However, these studies have relevant limitations:
besides small samples size and uneven representation of ages, they do
not report percentile distributions. Our study provided consistent, but
more reliable norms, due to sounder methods for this specific aim.
Recently, two other studies provided normative values for MTA in po-
pulation-based samples. However, in both studies (Cavallin et al., 2012;
Velickaite et al., 2018), the population investigated was grouped into
arbitrary age-homogeneous categories (i.e., only 60, 66, 72, 75, 78, 81,
84, and over-87 years olds) rather than using a continuous and more
representative age distribution. On the other hand, studies on norma-
tive PA distribution in population-based samples are still missing. To
our knowledge, this is the first study obtaining normative values for
both scales from a representative population-based sample of cogni-
tively unimpaired subjects with a wide and continuous age range. Our
normative values are consistent with the age-related cut-offs proposed
previously, indicating as normal MTA≤1 below age 60, MTA≤2 at
60–80, and MTA up to 4 beyond age 80, and PA≤1 below age 60, and
PA≤2 beyond 60 (Table 3). On the whole, this consistency in the data
suggests that these normative values, although obtained exclusively
from an Italian sample, can appropriately be used for other countries,
especially the European ones.
As expected in a cognitively intact population, the scores distribu-
tion is markedly skewed. The high prevalence of subjects scoring MTA 1
suggests that a unilateral widening of the choroid fissure is a relatively
common finding in the general population, possibly related to a phy-
siological asymmetry in the rotation of the hippocampal head (Bronen
and Cheung, 1991; Lucarelli et al., 2013). On the other hand, among the
linear measures of cortical atrophy, the width of the temporal horn
(MTA=2) seems to be particularly sensitive to the early pathological
change (Frisoni et al., 1996). Likewise, the fact that 38% of subjects
score PA=1 supports the idea that a slight enlargement of the cortical
sulci may be a common finding, probably related to physiological
aging, as also observed in voxel-based morphometry studies (Lemaitre
Table 1











70–79 (N=77) ≥80 (N=14)
Sociodemographic features
Age, years, mean± SD 50±15 25±3 35±3 45±3 54±3 64±3 74±3 82±1
Gender, females, N (%) 572 (61%) 62 (74%) 103 (64%) 126 (60%) 123 (61%) 105 (56%) 46 (60%) 7 (50%)
Education, years,
mean±SD
11.2± 4.5 14.6± 3.2 12.5± 4.2 11.2± 3.8 11.1± 4.6 9.5± 4.4 9.1±4.8 9.9±5.1
APOE-ε4 status
ε4 non-carriers, N (%) 430 (81%) 30 (83%) 61 (81%) 91 (76%) 98 (80%) 101 (82%) 44 (96%) 5 (62%)
ε4 heterozygous, N (%) 91 (17%) 6 (17%) 12 (16%) 25 (21%) 23 (19%) 20 (16%) 2 (4%) 3 (38%)
ε4 homozygous, N (%) 9 (2%) 0 (0%) 2 (3%) 3 (3%) 1 (1%) 3 (2%) 0 (0%) 0 (0%)
Cognition
MMSE, mean± SD 28.4± 1.4 28.7± 1.6 28.3± 1.5 28.4± 1.5 28.4± 1.4 28.1± 1.5 27.8± 1.5 26.8± 2.0
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et al., 2012; Thambisetty et al., 2010). The presence of high scores (up
to 4) in our healthy subjects over age 80 confirms that MTA is not useful
in distinguishing between healthy and cognitively impaired individuals
in this age range, consistently with previous evidence (Claus et al.,
2017) and daily clinical practice. Also etiological biomarkers have a
lower informative value with increasing age (Jansen et al., 2015). MTA
retains diagnostic utility in younger age ranges, representing an im-
portant marker useful to support the presence of neurodegeneration
plausibly related to Alzheimer's or related disorder.
In our sample, the association of MTA and PA with age, gender and
education is also in line with previously reported data (Rhodius-
Meester et al., 2017; Cavallin et al., 2012). Older age was associated to
higher scores for both scales (p< .001), and thus higher 50th and 90th
percentiles, reflecting age-related volumetric decline, known to affect
mainly the hippocampal head (Jack Jr. et al., 1997), the parietal lobe
and precuneus (Bourisly et al., 2015). In our study, gender did not af-
fect MTA, although a trend for greater atrophy was observed in males in
the last age decades taken into consideration. Velickaite et al. (2018)
recently reported a similar gender-related trend for MTA, but they also
identified an interaction between gender and education, with lower
scores in females with low education. We did not observe any inter-
action among the three confounders. On the other hand, gender showed
a significant effect on PA in the whole sample, consistent with cortical
morphometry studies showing greater levels of atrophy in men
Fig. 2. MTA and PA scores distribution by age decades.
Left panels: Scatterplots of MTA (above) and PA (below) scores distributions. Right panels: heat plot of the 90th percentile distributions (green squares= scores
under 90th percentile; red squares= scores over 90th percentile).
Table 2
MTA and PA scores by age decades in cognitively-unimpaired individuals.
Decade MTA PA
Range IQR Percentile distribution Range IQR Percentile distribution
≤50th ≤90th ≤50th ≤90th
20–29 0–2 0–1 0–1 0–1 0–1 0–0 0 0–1
30–39 0–2 0–1 0–1 0–1 0–2 0–0 0 0–1
40–49 0–2 0–1 0–1 0–1 0–2 0–1 0 0–1
50–59 0–2 0–1 0–1 0–1 0–2 0–1 0–1 0–1
60–69 0–3 0–1 0–1 0–1–2 0–3 1–1 0–1 0–1–2
70–79 0–3 1–2 0–1 0–1–2 0–3 1–2 0–1 0–1–2
≥80 0–4 1–3 0–1–2 0–1–2–3–4 1–2 1–2 0–1–2 0–1–2
Table reports scores' range, interquartile range (IQR), 50th and 90th percentiles.
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(Thambisetty et al., 2010). However, comparisons by age groups failed
to identify gender-specific percentile distributions, in agreement with
what already reported by Ferreira et al. (2015). Associations between
temporal and parietal volume measurements and confounders, such as
gender and education, are reported in middle-aged and elderly popu-
lations (Rhodius-Meester et al., 2017; Cavallin et al., 2012; Velickaite
et al., 2018; Thambisetty et al., 2010; Jiang et al., 2014), but not in
younger age ranges. This suggests that, in the last age decades, different
rates of atrophy in specific subgroups should be kept in mind for a
correct radiological assessment. The underlying presence of patholo-
gical aging, which remains clinically asymptomatic due to the com-
pensatory effect of the individual brain reserve, as well as of anatomical
variants or regional conformational anomalies, may contribute to these
differences. Therefore, the normative values reported in this and in
previous studies denote measures compatible with cognitive normality,
but that do not necessarily correspond to the full brain health. On the
other hand, using neurodegeneration biomarkers (CSF or PET) to ex-
clude an underlying pathological aging (amyloidosis or tauopathy), and
produce more robust norms, is questionable as to current clinical use
and relative to current definitions of cognitive normality. Robust norms
identify “disease-free” subjects not-representative of the general cog-
nitively unimpaired population; on the other hand, such norms may be
useful to identify pathological aging in the pre-clinical stage, and help
define eligibility to possible disease-modifying treatments. Future re-
search is warranted in this direction.
The prevalence of APOE-ε4 in our sample (19%) was similar to that
reported in the Conselice Study of Brain Aging (15%), a previous Italian
population-based survey conducted from 1999 to 2000 to measure
dementia risk factors (Ravaglia et al., 2006). The lack of significant
differences of APOE-ε4 prevalence in subjects with scores below- versus
those with score beyond the 90th percentile cut-offs, and the lack of
differences among the two distributions failed to demonstrate any im-
pact of APOE on MTA and PA per each age decade in the normal Italian
population. As widely reported in the literature, the ε4 allele of APOE
gene causes a dose-dependent increase in risk of developing AD (Corder
et al., 1993), and thus atrophy. However, the evidence concerning the
effect of ε4 on hippocampal and parietal volume in healthy subjects,
remains controversial, in particular in subjects over 40 (Espeseth et al.,
2008). Recently, a voxel-based morphometry study on cognitively
healthy middle-aged subjects failed to detect significant APOE-asso-
ciated volume differences in the hippocampus and in the parietal lobe
(Ten Kate et al., 2016), in accordance with our results.
The main limitation of this study consists in the use of a convenience
sample, consisting of individuals who underwent MRI for neurological
disturbances other than cognitive impairment. However, besides the
demonstrated cognitive integrity, the convenience sample and the
healthy volunteers subsample also included in our study were similar in
all respects, assuring the representativity of the convenience sample.
Further analyses with other populations are needed to confirm the
supposed generalizability of these norms to other populations, in par-
ticular to the non-European ones, and to validate the 90th percentile
distributions in clinical samples.
The generation of normative values in samples known for being free
of incipient neurodegeneration based on biomarker assessment may
provide robust norms possibly allowing to detect dementing neurode-
generative disorders at earlier stages than current clinical standards.
However, also these norms may have limitations. In fact, also bio-
marker-based cohorts may not be exempt from selection bias (e.g. age
and education related to voluntary participation), as observed for the
US ADNI cohort (Petersen et al., 2010). In addition, the positivity to
biomarker for neurodegenerative conditions is not necessarily asso-
ciated to neither a present nor future development of cognitive dis-
orders (Jansen et al., 2015), and norms based on “super-normals”, also
known as “robust norms”, would lead to an excessive number of false
positives based on the current concept of clinical health.
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